MolecularPartners_Logo.jpg
Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19
January 18, 2022 01:00 ET | Molecular Partners
Agreement grants global rights of ensovibep to Novartis, who will lead further development and commercialization of the programFinancial terms include milestone payment of CHF150 million to Molecular...
MolecularPartners_Logo.jpg
Molecular Partners Reports Disclosure of Major Shareholder as per Swiss Stock Exchange Regulations
January 13, 2022 17:00 ET | Molecular Partners
ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
MolecularPartners_Logo.jpg
Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19
January 10, 2022 01:17 ET | Molecular Partners
Topline results from the randomized, placebo-controlled EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic...
MolecularPartners_Logo.jpg
Molecular Partners to Present at Upcoming Healthcare Investor Conferences
January 05, 2022 16:05 ET | Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
MolecularPartners_Logo.jpg
Molecular Partners to Host Oncology Day (Virtual)
December 15, 2021 01:00 ET | Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
MolecularPartners_Logo.jpg
Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology
December 14, 2021 01:00 ET | Molecular Partners
Collaboration to leverage world class capabilities of Molecular Partners DARPin platform with Novartis’ in radioligand therapy to explore the potential for novel targeted therapies for cancerNovartis...
MolecularPartners_Logo.jpg
Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies
December 12, 2021 16:00 ET | Molecular Partners
Laboratory studies using full Omicron pseudovirus confirm ensovibep maintains ability to neutralize the variant with very high potency, relative to substantial reductions in neutralizing potency...
MolecularPartners_Logo.jpg
Molecular Partners Highlights Upcoming Oncology Portfolio Presentations in December
December 09, 2021 01:00 ET | Molecular Partners
Program overview and study design for MP0317 to be presented at ESMO Immuno-OncologyPreclinical data supporting novel mechanism of AML candidate MP0533 to be presented at ASHOncology R&D Day to...
MolecularPartners_Logo.jpg
Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021
December 06, 2021 01:00 ET | Molecular Partners
First presentation of data from patients treated with ensovibep demonstrate the candidate to be safe and well-tolerated All patients exhibited reductions in viral load and complete COVID-19 clinical...
MolecularPartners_Logo.jpg
Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AML
December 03, 2021 01:00 ET | Molecular Partners
Research collaboration with leading acute myeloid leukemia (AML) experts, Professor Ochsenbein and Professor Riether from the Department of Medical Oncology, Inselspital, Bern University Hospital,...